Ignacio Matos
@matosignacio
Medical Oncologist focused in Early Drug Development. ESMO Translational Research Fellowship
ID: 1150665743236849664
15-07-2019 07:17:46
83 Tweet
160 Takipçi
91 Takip Edilen
Systematic review & meta-analysis finds diverse definitions of Hyperprogressive Disease, w incidence varying from 6-43% across studies; indicates need for establishing uniform + clinically relevant criteria. University Hospitals Kartik Sehgal ja.ma/3rgct35
TALENT study publication arrives on May the 4th 🌟😬💪🏼One of the highest response rate ever seen in #NeuroendocrineCancer with an MKI!! Enrique Grande J Hernando Paula Jimenez Fonseca Xavier Merino Lorena Trejo Grupo GETNE NET- ESPAÑA Vall d’Hebron Institute of Oncology (VHIO) SEOM Vall d'Hebron ascopubs.org/doi/abs/10.120…
🚨🥁🥁🥁Huge win for RET+ patients. So honored to present 2 concurrent publications The Lancet Oncology + The Lancet Diabetes & Endocrinology 👉 Pralsetinib for RET + Lung & Thyroid cancer ARROW trial leading to FDA approval🎯ASCO #ASCO21 #LCSM #thycsm bit.ly/2SpVhNp bit.ly/3goE92q
Happy to share our contribution to improve patient selection for oncology early phase clinical trials (PIPO tool): 🔗Publication: sciencedirect.com/science/articl… ➡️Tool: pipo.vhio.net Team Ignacio Matos @ElenaGarralda Anna Pedrola Roger Berche Rodrigo Dienstmann_MD_MBA Vall d’Hebron Institute of Oncology (VHIO)
It was a pleasure to do a recent podcast with Seth Bannon on my Cell Press paper on why some respond to immunotherapies while others do not. Check it out! Thanks so much for the opportunity to highlight this work. Full episode here: translation.simplecast.com/episodes/what-…
Very impressing data presented at #ESMO2021 by Dr. Martinez Vall d'Hebron exploring durvalumab combinations with novel mAb in pts with LA-NSCLC treated with CRT (Phase II COSTAR trial).
#ESMO2021 Rockstar J Hernando talking about the influence of ICI in subsequent treatments in NETs and NECs. Well done!! New design concepts to try to bring immunotherapy to our NET patients 👍🏼💪🏼 Proud of you 👏🏼 ESMO - Eur. Oncology Grupo GETNE Vall d’Hebron Institute of Oncology (VHIO) Vall d'Hebron NET- ESPAÑA SEOM
🙏 Por favor RT 🚨📢 ATENCIÓN: BUSCAMOS 🩺Médico especialista en Oncología Médica 🦴para una plaza de facultativo en #sarcoma 🏥en Vall d’Hebron Institute of Oncology (VHIO) - centro de referencia nacional y europeo 🧪y con ganas de aprender y participar en #EnsayosClínicos #Investigación ➡️vhio.net/ref-1_2022-med…
Delighted to share our meta-analysis to investigate the benefit of immune checkpoint inhibitors and chemotherapy in 1L triple-negative breast cancer in subgroup analysis (n=2400). Special thanks to Tomás Pascual and @OrtegaTolosa SOLTI #cancerresearch 🔗Publication cancertreatmentreviews.com/article/S0305-…
Madrid acoge la 1ª reunión española de nuevas terapias en desarrollo precoz contra el cáncer cancercenter.cun.es/noticias/prime… Organizada por el Cancer Center Clínica Universidad de Navarra y avalada por SEOM, reúne a especialistas de más de 15 hospitales internacionales #ensayosclínicos
Hito en la atención en cáncer en España. 🏥 El Cancer Center Clínica Universidad de Navarra (#CCUN) ya ofrece la atención integral al paciente oncológico que la #UE pide para 2030. Descubre más 👉cancercenter.cun.es/noticias/centr… #Oncology #Salud #España #Cancer Cima Universidad de Navarra